Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
- PMID: 17954690
- PMCID: PMC2223911
- DOI: 10.1128/AAC.00719-07
Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
Abstract
Increasingly frequent reports have described the in vivo loss of daptomycin susceptibility in association with clinical treatment failures. The mechanism(s) of daptomycin resistance is not well understood. We studied an isogenic set of Staphylococcus aureus isolates from the bloodstream of a daptomycin-treated patient with recalcitrant endocarditis in which serial strains exhibited decreasing susceptibility to daptomycin. Since daptomycin is a membrane-targeting lipopeptide, we compared a number of membrane parameters in the initial blood isolate (parental) with those in subsequent daptomycin-resistant strains obtained during treatment. In comparison to the parental strain, resistant isolates demonstrated (i) enhanced membrane fluidity, (ii) increased translocation of the positively charged phospholipid lysyl-phosphotidylglycerol to the outer membrane leaflet, (iii) increased net positive surface charge (P < 0.05 versus the parental strain), (iv) reduced susceptibility to daptomycin-induced depolarization, permeabilization, and autolysis (P < 0.05 versus the parental strain), (v) significantly lower surface binding of daptomycin (P < 0.05 versus the parental strain), and (vi) increased cross-resistance to the cationic antimicrobial host defense peptides human neutrophil peptide 1 (hNP-1) and thrombin-induced platelet microbicidal protein 1 (tPMP-1). These data link distinct changes in membrane structure and function with in vivo development of daptomycin resistance in S. aureus. Moreover, the cross-resistance to hNP-1 and tPMP-1 may also impact the capacity of these daptomycin-resistant organisms to be cleared from sites of infection, particularly endovascular foci.
Figures
References
-
- Bayer, A. S., P. J. McNamara, M. R. Yeaman, L. I. Kupferwasser, N. Lucindo, T. Jones, H.-G. Sahl, and R. A. Proctor. 2006. Disruption of the complex I NADH oxidoreductase gene (snoD) in Staphylococcus aureus is associated with reduced susceptibility to the microbicidal activity of thrombin-induced platelet microbicidal protein 1. J. Bacteriol. 188:211-222. - PMC - PubMed
-
- Bayer, A. S., R. Prasad, J. Chandra, A. Koul, A. Verma, R. A. Skurray, N. Firth, M. Brown, S.-P. Koo, and M. R. Yeaman. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced microbicidal protein is associated with alterations in membrane fluidity. Infect. Immun. 68:3548-3553. - PMC - PubMed
-
- Burkhart, B. M., R. M. Gassman, D. A. Langs, W. A. Pangborn, W. L. Duax, and V. Pletnev. 1999. Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers 51:129-144. - PubMed
-
- Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
